Dermatology · PsoriasisRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for Brodalumab (Siliq) by Valeant

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/13/2026, 6:33:15 PM

Assessment confidence: 58% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for Brodalumab (Siliq) is significant as it may strengthen Valeant's competitive position in the psoriasis market. This development necessitates close monitoring of the approval timeline and potential market reactions from competitors. Regulatory context from FDA (IND Application Reporting: IND Safety Reports) supports the near-term read. Assessment grounded in 21 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should evaluate the potential market response and adjust strategies for competing psoriasis treatments. The strongest clinical anchor is The Effect of SuJok Application on Dysmenorrhea and Quality of Life in Young People With Primary Dysmenorrhea: (ClinicalTrials.gov), moderate corpus alignment. In Dermatology · Psoriasis, 7 regulatory and 3 competitive items passed relevance filtering for competitors in dermatology.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Supplemental Application for BRILINTA (Ticagrelor) (Humanexa Signals) — sponsor/company relevance (astrazeneca). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This acceptance may enhance Valeant's position in the psoriasis market, potentially impacting competitors with similar therapies.

Regulatory Outlook

Regulatory risk is concentrated around IND Application Reporting: IND Safety Reports (FDA). Moderate corpus alignment. The acceptance of this supplemental application indicates a positive regulatory trajectory, but the final approval outcome remains to be seen, which could affect compliance and market readiness.

Key Risks

Elevated medium regulatory exposure for competitors in dermatology could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, Brodalumab could capture additional market share in the psoriasis segment, impacting revenue projections for both Valeant and its competitors.
Upside for competitors in dermatology may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Upside for competitors in dermatology may improve if Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should evaluate the potential market response and adjust strategies for competing psoriasis treatments.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's review and any subsequent announcements regarding approval outcomes.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

IND Application Reporting: IND Safety Reports
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Investigational New Drug (IND) Application
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA AP — SILIQ (SUPPL)
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ACYCLOVIR (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — NITROGLYCERIN (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — VARENICLINE TARTRATE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

The Effect of SuJok Application on Dysmenorrhea and Quality of Life in Young People With Primary Dysmenorrhea:
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: Phase 3 Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Superficial Cervical Block Application on Postoperative Opioid Consumption in Patients Undergoing Anterior Cervical Discectomy Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves Supplemental Application for BRILINTA (Ticagrelor)
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Supplemental Application for Wegovy (Semaglutide)
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

competitors in dermatology

Commercial impact

medium

If approved, Brodalumab could capture additional market share in the psoriasis segment, impacting revenue projections for both Valeant and its competitors.

Regulatory impact

medium

The acceptance of this supplemental application indicates a positive regulatory trajectory, but the final approval outcome remains to be seen, which could affect compliance and market readiness.

What to watch

Monitor the timeline for the FDA's review and any subsequent announcements regarding approval outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.